Align Tech (ALGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from Bank of America Securities maintained a Sell rating on the stock and has a $195.00 price target.
Michael Ryskin has given his Sell rating due to a combination of factors related to Align Tech’s recent updates and market conditions. Despite Align Tech’s impressive technological advancements and innovation, Ryskin maintains a cautious outlook due to structural and market challenges that could limit the company’s growth potential. The company’s updated long-range plan (LRP) projects a more realistic growth rate of 5-15% in the 2026-2028 period, which is a reduction from their previous, more aggressive targets.
While the revised growth targets are seen as more achievable, Ryskin expresses skepticism about the company’s ability to achieve over 15% growth beyond 2029, given current market trends and consumer sentiment. Although Align Tech continues to innovate with new technologies and enhancements, Ryskin remains concerned about the ambitious nature of the growth targets without significant uptake of key growth drivers. Consequently, he maintains a Sell rating, reflecting a belief that the stock’s upside is limited under current conditions.
Ryskin covers the Healthcare sector, focusing on stocks such as Illumina, Danaher, and Waters. According to TipRanks, Ryskin has an average return of -0.4% and a 45.68% success rate on recommended stocks.